

# The Fourth iCeMS SEMINAR

## Immunotoxins in 2008: Successes and Challenges: Effective Treatment of Drug Resistant Hairy Cell Leukemia by Immunotoxin BL22

Lecturer: Dr. Ira Pastan

Head, Molecular Biology Section  
Chief, Laboratory of Molecular Biology, Center for Cancer Research  
National Cancer Institute, National Institutes of Health, U. S. A.

Moderator: Dr. Kazumitsu Ueda

Professor of iCeMS and Faculty/Graduate School of Agriculture  
Kyoto University

**Date & Time:** **Wednesday, April 23, 2008, 16:00-17:00**

**Venue:** **Roof Terrace**

Institute for Frontier Medical Sciences, 5F of the East Building

Most cancers cannot be cured once they have metastasized. To develop a new treatment for metastatic cancer, Dr. Pastan and his team have used genetic engineering to modify a powerful bacterial toxin, Pseudomonas exotoxin A (PE), so that instead of killing normal cells it selectively kills cancer cells. PE-based anti-cancer agents have been produced by replacing the binding domain of PE with the Fv fragment of an antibody or with a growth factor that binds to cancer cells. These agents are termed "recombinant immunotoxins". They are currently conducting clinical trials with some of these immunotoxins. In this presentation, Dr. Pastan will present his recent progress of the clinical applications of BL22, which targets CD22 on B cell leukemias and lymphomas.

**Contact:** Aki Kusumi at [akusumi@frontier.kyoto-u.ac.jp](mailto:akusumi@frontier.kyoto-u.ac.jp) / Fax: 751-4113

**Held by:** iCeMS (Institute for Integrated Cell-Material Sciences), Faculty / Graduate School of Agriculture  
The Institute for Frontier Medical Sciences, Kyoto University

**Co-held by:** Japan Society for Bioscience, Biotechnology, and Agrochemistry